It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infected a substantial proportion of Chinese population, and understanding the factors underlying the severity of the disease and fatality is valuable for future prevention and clinical treatment. We recruited 64 patients with invasive ventilation for COVID-19 and performed metatranscriptomic sequencing to profile host transcriptomic profiles, plus viral, bacterial, and fungal content, as well as virulence factors and examined their relationships to 28-day mortality were examined. In addition, the bronchoalveolar lavage fluid (BALF) samples from invasive ventilated hospital/community-acquired pneumonia patients (HAP/CAP) sampled in 2019 were included for comparison. Genomic analysis revealed that all Omicron strains belong to BA.5 and BF.7 sub-lineages, with no difference in 28-day mortality between them. Compared to HAP/CAP cohort, invasive ventilated COVID-19 patients have distinct host transcriptomic and microbial signatures in the lower respiratory tract; and in the COVID-19 non-survivors, we found significantly lower gene expressions in pathways related viral processes and positive regulation of protein localization to plasma membrane, higher abundance of opportunistic pathogens including bacterial Alloprevotella, Caulobacter, Escherichia-Shigella, Ralstonia and fungal Aspergillus sydowii and Penicillium rubens. Correlational analysis further revealed significant associations between host immune responses and microbial compositions, besides synergy within viral, bacterial, and fungal pathogens. Our study presents the relationships of lower respiratory tract microbiome and transcriptome in invasive ventilated COVID-19 patients, providing the basis for future clinical treatment and reduction of fatality.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 8th Medical Center of Chinese PLA General Hospital, College of Pulmonary & Critical Care Medicine, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
2 Chinese Academy of Sciences, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309)
3 Chinese Academy of Sciences, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
4 Chinese Academy of Sciences, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309); Baotou Teacher’s College, Faculty of Biological Science and Technology, Baotou, China (GRID:grid.510531.3) (ISNI:0000 0004 1767 3666)
5 PLA Strategic Support Force Medical Center, Department of Respiratory Medicine, Beijing, China (GRID:grid.488137.1) (ISNI:0000 0001 2267 2324)
6 Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Department of Respiratory and Critical Care Medicine, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
7 the 8th Medical Center of Chinese PLA General Hospital, Respiratory Research Institute, Department of Pulmonary & Critical Care Medicine, Beijing Key Laboratory of OTIR, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
8 Shougang hospital of Peking University, Beijing, China (GRID:grid.497870.5) (ISNI:0000 0004 4911 5693)
9 Beijing Changping Hospital, Department of Respiratory Medicine, Beijing, China (GRID:grid.410726.6)
10 Capital Medical University, Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
11 the 8th medical center of Chinese PLA general hospital, Pulmonary research institute, Senior Department of Respiratory and Critical Care Medicine, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
12 Chinese PLA General Hospital, College of Pulmonary & Critical Care Medicine, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
13 China Aerospace Science & Industry Corporation 731 hospital, Beijing, China (GRID:grid.495325.c) (ISNI:0000 0004 0508 5971)
14 Aerospace Center Hospital, Department of Respiratory and Critical Care Medicine, Beijing, China (GRID:grid.464204.0) (ISNI:0000 0004 1757 5847)
15 Vision Medicals Center for Infectious Diseases, Guangzhou, China (GRID:grid.508230.c)